Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
Novel Coronavirus (2019-nCoV) Infection in Humans: A Scoping Review and Meta-Analysis
65 Pages Posted: 13 Mar 2020More...
Background: A growing body of literature on the 2019 novel coronavirus (2019-nCoV) is becoming available but a synthesis of available data has not been conducted. We performed a scoping review of currently available clinical, epidemiological, laboratory, and chest imaging data related to the 2019-nCoV infection.
Methodology: We searched MEDLINE, Cochrane CENTRAL, EMBASE, Scopus and LILACS from January 1st, 2019 to February 24th, 2020. Study selection, data extraction and risk of bias assessment were performed by two independent reviewers. Qualitative synthesis was conducted, and random-effects models were applied to estimate pooled results.
Findings: Sixty-one studies were included (101,905 patients). The most common disease-related symptoms were fever (84%, 95% confidence interval (CI) 77-91%; n=2,452), cough (63%, 95% CI 55-70%; n=2,027), and muscle aches and/or fatigue (27%, 95% CI 19-37%; n=1,742). Laboratory findings were described in a lower number of patients, and revealed lymphopenia (0.93x109/L, 95% CI 0.83-1.03x109/L, n=464) and abnormal C-reactive protein (33.72mg/dL, 95% CI 21.54-45.91mg/dL, n=1637). Radiological findings varied, but mostly described ground glass opacities and consolidation. Data on treatment options were limited. All-cause mortality was 1.1% (95% CI 0.1-2.7%; n=51,673). Epidemiological studies showed that mortality was higher in males and elderly patients.
Interpretation: The majority of reported clinical symptoms and laboratory findings related to 2019-nCoV infection are non-specific. Clinical suspicion, accompanied by a relevant epidemiological history, should be followed by early imaging and virological assay.
Funding Statement: No funding was obtained for this study.
Declaration of Interests: None.
Ethics Approval Statement: The authors stated that ethics approval was not necessary.
Keywords: Coronavirus; Evidence-based Medicine; Symptom Assessment; public health; 2019- nCoV
Suggested Citation: Suggested Citation